Dupilumab-associated (hyper)eosinophilia in patients with atopic dermatitis: a single-centre cohort study of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry

This study investigated the incidence and progression of (hyper)eosinophilia in patients with atopic dermatitis (AD) treated with dupilumab, using data from the TREAT NL registry cohort. In total, 38.5% of patients had (hyper)eosinophilia at baseline and/or during dupilumab treatment. (Hyper)eosinophilia was present at baseline in 43 (55.8%) patients and developed in 34 (44.2%) patients during treatment. Eosinophilia was transient, peaking at 6 months and normalizing by 18–24 months. One patient discontinued dupilumab due to persistent hypereosinophilia, but generally, eosinophilia did not affect treatment outcomes. In conclusion, dupilumab is found viable for patients with AD regardless of baseline eosinophilia, with temporary increases in eosinophil counts that are often not clinically significant.